New Delhi, May 6: Pharmaceutical major Ranbaxy Laboratories Limited has got a tentative approval from authorities in the United States to make and sell a generic version of Pfizer’s anti-fungal drug Diflucan.
Ranbaxy today said the tentative approval is for Fluconazole tablets, which is therapeutically equivalent to Diflucan. The tablets will be marketed in the strengths of 50mg, 100mg, 150 mg and 200 mg.
Diflucan is indicated for the treatment of vaginal infection, oropharyngeal and esophageal infection, as also cryptococcal meningitis.
Fluconazole is also indicated for patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and or radiation therapy.
Fluconazole in its tablet format comprise 68 per cent of the total $ 624.7 million market for this fungal medication.